Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

En studie av Orelabrutinib hos patienter med sekundär progressiv multipel skleros

30 oktober 2026 uppdaterad av: Zenas BioPharma (USA), LLC

En fas 3, randomiserad, dubbelblind, effekt- och säkerhetsstudie som jämför Orelabrutinib med placebo hos patienter med icke-aktiv sekundär progressiv multipel skleros

Orelabrutinib is a CNS-penetrable BTK inhibitor. This is a phase 3, randomized, double-blind, parallel-group, multicenter study to evaluate the efficacy and safety of orelabrutinib compared with placebo in patients with non-active Secondary Progress MS. Patients will be treated for approximately 24 to 60 months, with a minimum treatment duration of 12 months. The study will enroll approximately 990 subjects in a 2:1 randomization (orelabrutinib: placebo), globally.

Studieöversikt

Status

Rekrytering

Detaljerad beskrivning

This is a phase 3, randomized, double-blind, parallel-group, multicenter study to evaluate the efficacy and safety of orelabrutinib compared with placebo in patients with naSPMS. The study will enroll approximately 990 subjects in a 2:1 randomization (orelabrutinib: placebo), globally.

The study consists of the following periods:

  • Screening Period: Up to 4 weeks.
  • Treatment Period: The duration of treatment will vary for individual participants ranging from approximately 24 to 60 months, depending on the time of recruitment. A month is defined as a period of 28 days by convention.
  • Double-blinded (DB) Treatment: All eligible participants will be randomized at 2:1 ratio to accept orelabrutinib QD or placebo during the DB treatment period. The study will be unblinded when all participants in the DB period have reached a minimum treatment duration of 12 months at the time of primary analysis timing cutoff.
  • Open-label (OL) Treatment: Participants with 24-week CDP as assessed by EDSS are eligible for 2-year open-label orelabrutinib treatment.
  • Safety Follow-Up Period: It will last 4 weeks. The safety follow-up period will begin when the participants discontinue from the treatment before the end of the trial for any reasons or complete the trial but do not enter the long-term safety study (LTS) (see below).

All active study participants will have a final end of study (EOS) visit within 4 weeks of the study end date. Participants who are receiving IMP in DB or OL but do not consent to or are not eligible for enrollment in the LTS study, must return for a final safety follow-up visit 4 weeks later. For participants who intend and are eligible to join the LTS, open-label treatment with orelabrutinib will continue and no safety follow-up will occur.

Studietyp

Interventionell

Inskrivning (Beräknad)

990

Fas

  • Fas 3

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studera Kontakt Backup

Studieorter

    • New South Wales
      • Kogarah, New South Wales, Australien, 2217
        • Rekrytering
        • Southern Neurology Suite 2
    • Limburg
      • Overpelt, Limburg, Belgien, 3900
        • Rekrytering
        • MS-Netwerk Limburg - Revalidatie
      • Pleven, Bulgarien, 5800
        • Rekrytering
        • Avis Medica Hospital Pleven
    • Plovdiv
      • Plovdiv, Plovdiv, Bulgarien, 4000
        • Rekrytering
        • Medical Center Nevrocentrum
    • Sofia
      • Sofia, Sofia, Bulgarien, 1680
        • Rekrytering
        • Diagnostic and Consultative Center Convex
      • Sofia, Sofia, Bulgarien, 1510
        • Rekrytering
        • Medical Center Hera EOOD
    • Tarnovo
      • Veliko Tarnovo, Tarnovo, Bulgarien, 5000
        • Rekrytering
        • Medical Center Medica Plus OOD
    • Harju
      • Tallinn, Harju, Estland, 10617
        • Rekrytering
        • Astra clinic (Clinic4U)
    • Gard
      • Nîmes, Gard, Frankrike, 30029
        • Rekrytering
        • Centre Hospitalier Universitaire de Nimes (CHU) - Hopital Universitaire Caremeau
    • Arizona
      • Phoenix, Arizona, Förenta staterna, 85032
        • Rekrytering
        • Arizona Neuroscience Research, LLC
      • Scottsdale, Arizona, Förenta staterna, 85253
        • Rekrytering
        • Perseverance Research Center, LLC (PRC)
    • California
      • Fullerton, California, Förenta staterna, 92835
        • Rekrytering
        • Fullerton Neurology and Headache Center
      • Torrance, California, Förenta staterna, 90502-2006
        • Rekrytering
        • Harbor-UCLA Medical Center - The Lundquist Institute (Los Angeles Biomedical Research Institute (LA BioMed))
      • West Hollywood, California, Förenta staterna, 90048
        • Rekrytering
        • Regina Berkovich MD, PhD Inc
    • Florida
      • Boca Raton, Florida, Förenta staterna, 33487
        • Rekrytering
        • SFM Clinical Research, LLC
      • Bradenton, Florida, Förenta staterna, 34209
        • Rekrytering
        • Nova Clinical Research, LLC
      • Clearwater, Florida, Förenta staterna, 33761
        • Rekrytering
        • MS and Neuromuscular Center of Excellence
      • Maitland, Florida, Förenta staterna, 32751
        • Rekrytering
        • Neurology Associates
      • Naples, Florida, Förenta staterna, 34105
        • Rekrytering
        • Aqualane Clinical Research
      • Tampa, Florida, Förenta staterna, 33612
        • Rekrytering
        • University of South Florida Department of Neurology - MS Division
    • Indiana
      • Indianapolis, Indiana, Förenta staterna, 46256
        • Rekrytering
        • Josephson Wallack Munshower Neurology, Pc Suite 225
    • Kansas
      • Kansas City, Kansas, Förenta staterna, 66160
        • Rekrytering
        • University of Kansas Medical Center
      • Roeland Park, Kansas, Förenta staterna, 66205
        • Rekrytering
        • KC Research Center, PA Neurology Research Dept
    • Massachusetts
      • Boston, Massachusetts, Förenta staterna, 02131
        • Indragen
        • Boston Clinical Trials
      • Worcester, Massachusetts, Förenta staterna, 01655
        • Rekrytering
        • University of Massachusetts Memorial Medical Center
    • Michigan
      • Rochester Hills, Michigan, Förenta staterna, 48307
        • Rekrytering
        • Profound Research LLC at Oakland Neurology Center
    • Missouri
      • St Louis, Missouri, Förenta staterna, 63110
        • Rekrytering
        • Washington University School of Medicine
    • New Mexico
      • Albuquerque, New Mexico, Förenta staterna, 87131
        • Rekrytering
        • University Of New Mexico School Of Medicine
    • New York
      • New York, New York, Förenta staterna, 10029
        • Rekrytering
        • Mount Sinai Medical Center
    • Ohio
      • Columbus, Ohio, Förenta staterna, 43235
        • Rekrytering
        • The Boster Center for Multiple Sclerosis
      • Columbus, Ohio, Förenta staterna, 43221
        • Rekrytering
        • The Ohio State University Wexner Medical Center (OSUWMC)
    • Oklahoma
      • Oklahoma City, Oklahoma, Förenta staterna, 73104
        • Rekrytering
        • OMRF Multiple Sclerosis Center of Excellence
    • South Carolina
      • Greenville, South Carolina, Förenta staterna, 29605
        • Rekrytering
        • Premier Neurology
    • Tennessee
      • Cordova, Tennessee, Förenta staterna, 38018
        • Rekrytering
        • Neurology Clinic, P.C.
    • Texas
      • San Antonio, Texas, Förenta staterna, 78258
        • Rekrytering
        • Lone Star Neurology
      • Sherman, Texas, Förenta staterna, 75092
        • Rekrytering
        • Texas Institute for Neurological Disorders - Sherman
      • Tbilisi, Georgien, 0114
        • Rekrytering
        • LTD Pineo Medical Ecosystem
      • Tbilisi, Georgien, 0186
        • Rekrytering
        • Raymann, LLC
      • Tbilisi, Georgien, 0159
        • Rekrytering
        • NNLE Jo Ann University Hospital
      • Tbilisi, Georgien, 0186
        • Rekrytering
        • Caucasus Medical Center Ltd
    • K'alak'i T'bilisi
      • Tbilisi, K'alak'i T'bilisi, Georgien, 0114
        • Rekrytering
        • JSC Curatio
    • Saburtalo
      • Tbilisi, Saburtalo, Georgien, 0160
        • Rekrytering
        • MD Georgia Staff Physician MediClub Georgia
    • Athens
      • Cholargós, Athens, Grekland, 15562
        • Rekrytering
        • Metropolitan General Hospital
    • Attica
      • Athens, Attica, Grekland, 11526
        • Rekrytering
        • Errikos Dunant Hospital
    • Chieti
      • Chieti, Chieti, Italien, 66100
        • Rekrytering
        • University G. D'Annunzio of Chieti-Pescara
    • Isernia/Molise
      • Pozzilli, Isernia/Molise, Italien, 86077
        • Rekrytering
        • IRCCS Istituto Neurologico Mediterraneo Neuromed
      • Zagreb, Kroatien, 10 000
        • Rekrytering
        • Klinicki Bolnicki Centar Zagreb-Rebro
    • Kauno
      • Kaunas, Kauno, Litauen, 50161
        • Rekrytering
        • Hospital of Lithuanian University of Health Sciences
      • Lublin, Polen, 20-064
        • Rekrytering
        • Galen Clinic
      • Poznan, Polen, 15-540
        • Rekrytering
        • Prywatna Lecznica Certus Sp. z o.o.
      • Szczecin, Polen, 70-111
        • Rekrytering
        • EUROMEDIS Osrodek Badan Klinicznych
      • Żory, Polen, 44-240
        • Rekrytering
        • Centrum Medyczne ProNeuro Żory
    • Kuyavian-Pomeranian Voivodeship
      • Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Polen, 85-605
        • Rekrytering
        • Centrum Medyczne INTERCOR Sp. z o.o.
    • Lublin Voivodeship
      • Lublin, Lublin Voivodeship, Polen, 20-601
        • Rekrytering
        • Malva Trials
      • Lublin, Lublin Voivodeship, Polen, 20-064
        • Rekrytering
        • Instytut Naukowo-Badawczy w Lublinie Sp. z o.o.
      • Lublin, Lublin Voivodeship, Polen, 20-064
        • Rekrytering
        • NZOZ Neuromed M. i M. Nastaj Sp.P
    • Lubusz Voivodeship
      • Nowa Sól, Lubusz Voivodeship, Polen, 67-100
        • Rekrytering
        • Twoja Przychodnia Centrum Medyczne Nowa Sól
    • Mazovian
      • Warsaw, Mazovian, Polen, 02-172
        • Rekrytering
        • MTZ Clinical Researcz Powered by pratia
    • Rzeszów
      • Rzeszów, Rzeszów, Polen, 35-323
        • Rekrytering
        • Nmedis sp. z o.o.
    • Silesian Voivodeship
      • Katowice, Silesian Voivodeship, Polen, 40-081
        • Rekrytering
        • Centrum Medyczne Pratia Katowice
      • Katowice, Silesian Voivodeship, Polen, 40-571
        • Rekrytering
        • MA-LEK Clinical Sp. z o.o.
      • Katowice, Silesian Voivodeship, Polen, 40-584
        • Rekrytering
        • NZOZ Novo Med
    • Upper Silesia
      • Katowice, Upper Silesia, Polen, 40-686
        • Rekrytering
        • Neuro Medic Clinic
    • Wielkopolska
      • Poznan, Wielkopolska, Polen, 61-853
        • Rekrytering
        • Nzoz Neuro-Kard Ilkowski I Partnerzy Spolka Partnerska Lekarzy
      • Poznan, Wielkopolska, Polen, 60-324
        • Rekrytering
        • Twoja Przychodnia PCM
    • Łódź Voivodeship
      • Lodz, Łódź Voivodeship, Polen, 91-743
        • Rekrytering
        • PRO SALUS Sp. z o.o. sp.k.
      • Lodz, Łódź Voivodeship, Polen, 90-324
        • Rekrytering
        • Centrum Neurologii Krzysztof Selmaj
      • Guaynabo, Puerto Rico, 00969
        • Rekrytering
        • Caribbean Center for Clinical Research
    • Constanța County
      • Constanța, Constanța County, Rumänien, 900123
        • Rekrytering
        • Spital Clinic CF Constanta
    • Suceava
      • Radauti, Suceava, Rumänien, 725400
        • Rekrytering
        • Spitalul Municipal Sf. Doctori Cosma si Damian Radauti
      • Kragujevac, Serbien, 34000
        • Rekrytering
        • University Clinical Centre of Kragujevac
      • Niš, Serbien, 18000
        • Rekrytering
        • Clinic of Neurology - Clinical Center Nis
    • Belgrade
      • Belgrade, Belgrade, Serbien, 11000
        • Rekrytering
        • University Clinical Centre of Serbia
    • A Coruña
      • A Coruña, A Coruña, Spanien, 15006
        • Rekrytering
        • Complejo Hospitalario Universitario A Coruña
    • Galicia
      • Vigo, Galicia, Spanien, 36312
        • Rekrytering
        • Hospital Alvaro Cunqueiro
    • Madrid
      • Madrid, Madrid, Spanien, 28007
        • Rekrytering
        • Hospital Gregorio Marañon
      • Majadahonda, Madrid, Spanien, 28222
        • Rekrytering
        • Hospital Universitario Puerta de Hierro de Majadahonda
    • Málaga
      • Málaga, Málaga, Spanien, 29016
        • Rekrytering
        • Vithas Hospital Parque San Antonio
    • Seville
      • Castilleja de la Cuesta, Seville, Spanien, 41950
        • Rekrytering
        • Hospital Vithas Nisa Sevilla
      • Choceň, Tjeckien, 56501
        • Rekrytering
        • NEUROHK, s.r.o.
      • Jihlava, Tjeckien, 58601
        • Rekrytering
        • Regional Hospital Jihlava
    • Hesse
      • Bad Homburg, Hesse, Tyskland, 61348
        • Rekrytering
        • Zentrum fur klinische Forschung Dr.Scholl GmbH
      • Vinnytsia, Ukraina, 21009
        • Rekrytering
        • Medical Clinical Investigational Center of Medical Center LLC Health Clinic
    • Chernivtsi Oblast
      • Chernivtsi, Chernivtsi Oblast, Ukraina, 58023
        • Rekrytering
        • Regional Municipal Non-commercial Enterprise Chernivtsi Emergency Medical Hospital
    • Ivano-Frankivs'k Oblast
      • Ivano-Frankivsk, Ivano-Frankivs'k Oblast, Ukraina, 76018
        • Rekrytering
        • CNE City Clinical Hospital #1 of Ivano-Frankivsk council
    • Lviv Oblast
      • Lviv, Lviv Oblast, Ukraina, 79000
        • Rekrytering
        • Limited Liability Company Medical Center Neuroclinic
      • Lviv, Lviv Oblast, Ukraina, 79029
        • Rekrytering
        • Limited Liability Company "Neurofocus"
      • Budapest, Ungern, 1145
        • Rekrytering
        • National Institute of Clinical Neurosciences
      • Tatabánya, Ungern, 2800
        • Rekrytering
        • Komarom-Esztergom Varmegyei Szent Borbala Korhaz
    • Komarom-Esztergom Vamegye
      • Esztergom, Komarom-Esztergom Vamegye, Ungern, 2500
        • Rekrytering
        • Valeomed Kft.

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år till 60 år (Vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  1. 18 to 60 years of age, inclusive, at the time of signing the informed consent.
  2. Participant must have a previous diagnosis of RRMS in accordance with 2024 McDonald criteria
  3. Participant must have a current diagnosis of SPMS in accordance with the clinical course criteria revised in 2013
  4. Participant must have documented evidence of disability progression independent of clinical relapse observed during the 24 months before screening. A written summary of the clinical evidence of disability progression must be discussed and aligned between the Investigator and the Sponsor's dedicated qualified person(s).
  5. Absence of clinical relapses for at least 24 months.

Exclusion Criteria:

  1. The patient has been diagnosed with primary progressive MS (PPMS) according to 2024 McDonald diagnostic criteria
  2. Immunologic disorder other than MS or any other conditions requiring corticosteroid therapy.
  3. History or current diagnosis of other neurological disorders that may mimic MS
  4. History or current diagnosis of progressive multifocal leukoencephalopathy
  5. Active, clinically significant viral, bacterial, or fungal infection
  6. History of any other significant active medical condition
  7. History of suicidal behavior within 6 months prior to Screening
  8. Any prior history of malignancy
  9. Patients on anticoagulation, or antiplatelet therapy
  10. Patients took strong/moderate CYP3A inhibitors or strong/moderate CYP3A inducers within 14 days
  11. Clinically significant laboratory abnormalities at Screening.
  12. Vaccination with live or live-attenuated virus vaccine within 1 month prior to Screening
  13. History of alcohol abuse or alcohol use disorder or other drug abuse within 12 months prior to screening.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Fyrdubbla

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Orelabrutinib Group

Orelabrutinib PO daily

Orelabrutinib orally

Placebo-jämförare: Placebo Group

Placebo PO daily

Placebo orally

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Time to onset of confirmed disability progression (CDP) events, confirmed over at least 24 weeks
Tidsram: Up to approximately 120 weeks

Expanded disability status scale (EDSS) score increase ≥ 1.0 point from baseline when the baseline score is ≤ 5.0, or ≥ 0.5 points from baseline when the baseline score is > 5.0

Up to approximately 120 weeks

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
12 Week CDP
Tidsram: Up to approximately 120 weeks

Time to onset of CDP events on EDSS, confirmed over at least 12 weeks

Up to approximately 120 weeks
T2 lesions on MRI
Tidsram: Up to approximately 120 weeks

The total number of new or enlarging T2 lesions on MRI scans of the brain

Up to approximately 120 weeks
24-week CDP-9-hole Peg Test
Tidsram: Up to approximately 120 weeks

Time to onset of CDP events on 9-hole Peg Test (9HPT), defined as ≥ 20% increase on 9HPT from baseline, confirmed over at least 24 weeks

Up to approximately 120 weeks
24-week CDP-T25FWT
Tidsram: Up to approximately 120 weeks

Time to onset of CDP events on Timed 25-Foot Walk Test (T25FWT), defined as ≥ 20% increase on T25FWT from baseline, confirmed over at least 24 weeks

Up to approximately 120 weeks
24-week CDI
Tidsram: Up to approximately 120 weeks

Time to onset of confirmed disability improvement (CDI) events on EDSS, defined as ≥ 1.0-point decrease on the EDSS score from baseline when the baseline score is ≤ 5.0, or ≥ 0.5 points from baseline when the baseline score is > 5.0, confirmed over at least 24 weeks

Up to approximately 120 weeks
24-week CDI-9HPT
Tidsram: Up to approximately 120 weeks

Time to onset of CDI events on 9HPT, defined as ≥ 20% decrease on the 9HPT score from baseline, confirmed over at least 24 weeks

Up to approximately 120 weeks
24-week CDI-T25FWT
Tidsram: Up to approximately 120 weeks

Time to onset of CDI events on T25FWT, defined as ≥ 20% decrease on the T25FWT score from baseline, confirmed over at least 24 weeks

Up to approximately 120 weeks
Symbol Digit Modalities Test
Tidsram: Up to approximately 120 weeks

The change in cognitive function as assessed by Symbol Digit Modalities Test (SDMT) from baseline to each scheduled visit

Up to approximately 120 weeks
Annualized relapse rate
Tidsram: Up to approximately 120 weeks

Annualized relapse rate (ARR) during the study period assessed by protocol-defined adjudicated relapses

Up to approximately 120 weeks
To evaluate the safety and tolerability of orelabrutinib
Tidsram: Up to approximately 120 weeks

Safety as assessed by the nature, severity, and incidence of adverse events (AEs) (graded according to National Cancer Institute-Common Terminology Criteria for AEs, NCI-CTCAE version 5.0);

Up to approximately 120 weeks

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

23 mars 2026

Primärt slutförande (Beräknad)

1 juni 2030

Avslutad studie (Beräknad)

1 juli 2030

Studieregistreringsdatum

Först inskickad

18 december 2025

Först inskickad som uppfyllde QC-kriterierna

19 december 2025

Första postat (Faktisk)

23 december 2025

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

4 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

30 oktober 2026

Senast verifierad

1 oktober 2026

Mer information

Termer relaterade till denna studie

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Ja

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera